Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLM1016 in Schizophrenia
NCT06799559Phase 3Active, not recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QLM1016 in schizophrenia, sponsored by Qilu Pharmaceutical. Started Oct 2025; status: active, not recruiting.
02
Drugs
QLM1016
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06799559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799559.